Once given FDA approval, the Senseonics Eversence System will be the fourth CGMS available in the U.S. It was submitted to the FDA for premarket approval last October, supported by data from a 90-patient pivotal trial of the device. The trial followed adults with type 1 or type 2 diabetes over 90 days of CGM sensor wearing. This is an implantable CGM system that is currently approved in Europe. The sensor sits just under your skin and can stay there for anywhere from 90-180 days.

Julia Greenstein, Ph. D. is the JDRF Vice President of Discovery Research, which includes early-stage programs across the JDRF portfolio. Dr. Greenstein has more than 20 years of experience in the corporate biotechnology arena, holding leadership positions that have helped accelerate discoveries to market.

Julia Greenstein discusses JDRF research into how beta cell stress and the immune system are contributing to the pathways of initiating and continuing the destruction of the beta cells in type 1 diabetes.

In this Exclusive Interview, Dr. Julia Greenstein talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the work at the JDRF to prevent diabetes and the encouraging results of the use of a cancer drug as a possible diabetes treatment.

In part 1 of this Exclusive Interview, Dr. Julia Greenstein talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about research plans at the JDRF.

In part 2 of this Exclusive Interview, Dr. Julia Greenstein talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about potential for successfully preventing diabetes.

In part 3 of this Exclusive Interview, Dr. Julia Greenstein talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about a cancer drug that is showing potential in the treatment or even prevention of diabetes.

In part 4, the conclusion of this Exclusive Interview, Dr. Julia Greenstein talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the name and mission of the JDRF.

Last month, Bill, a cycling friend of mine, asked if I knew a good physician in the area. He was from Maine and this was the winter that he and his spouse were making their move to Florida permanent. My first choice was my own physician as he is a …

Female, 67 years of age, type 2 diabetes, class 2 diabetes, depression, hyperlipidemia, vitamin D deficiency plus more. Her A1C is 6.8% and her lipids are within goal. Her random glucose 2 hours after eating cookies was 118 today. Her glucose lowering meds are Trulicity, metformin, and Jardiance. She takes them as prescribed. Her endocrinologist recommended she meet with me. She refused until he recommended she see me the same day she was coming in to see another health care provider for her monthly infusion for another disease process to make getting here easier.